Published online before print December 10, 2007, doi: 10.1161/HYPERTENSIONAHA.107.098939
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2008;51:406.)
© 2008 American Heart Association, Inc.
Original Articles |
Ethnic and Genetic Determinants of Cardiovascular Response to the Selective 
2-Adrenoceptor Agonist Dexmedetomidine
From the Departments of Medicine and Pharmacology, Division of Clinical Pharmacology (D.K., E.A.F., M.M., G.G.S., A.J.J.W., C.M.S.), and the Department of Biomedical Statistics (W.D.D.), Vanderbilt University School of Medicine, Nashville, Tenn; the Department of Pharmacology, Drug Development and Therapeutics (M.S.), University of Turku, and Clinical Pharmacology, TYKSLAB, Hospital District of Southwest Finland, Turku, Finland.
Correspondence to C. Michael Stein, MD, Division of Clinical Pharmacology, 542 RRB, Vanderbilt University School of Medicine, Nashville, TN 37232. E-mail michael.stein{at}vanderbilt.edu
The 
2-adrenoceptor agonist clonidine reduces blood pressure more effectively in White than Black Americans despite similar degrees of sympatholysis. Functional genetic variation in receptor signaling mechanisms, for example in the β3 G-protein subunit (GNB3 C825T) and in the 2C-adrenoceptor subtype (ADRA2C del322–325), may affect drug responses. We examined the hypothesis that there are ethnic differences in the responses to the highly selective 2-agonist, dexmedetomidine, and that these genetic variants contribute to interindividual variability in drug responses. In a placebo-controlled, single-masked study, 73 healthy subjects (37 whites and 36 blacks) received 3 placebo infusions and then 3 incremental doses of dexmedetomidine (cumulative dose, 0.4 µg/kg), each separated by 30 minutes. Blood pressure, heart rate, and plasma catecholamine concentrations were determined after each infusion. We measured dexmedetomidine concentrations after the last infusion and determined ADRA2C del322–325 and GNB3 C825T genotypes. Dexmedetomidine lowered blood pressure and plasma catecholamine concentrations significantly (all P<0.001). There was substantial interindividual variability in the reduction of systolic blood pressure (range, 1 to 34 mm Hg) and plasma norepinephrine concentrations (range, 24 to 424 pg/mL). However, there were no differences between black and white subjects in dexmedetomidine responses (P>0.16 for all outcomes) before or after adjustment for covariates. Neither ADRA2C del322–325 nor GNB3 C825T genotypes affected the responses to dexmedetomidine (all P>0.66). There is large interindividual variability in response to the selective 2-AR agonist dexmedetomidine, and neither ethnicity nor ADRA2C and GNB3 genotypes contribute to it. Further studies to identify determinants of 2-AR–mediated responses will be of interest.
Key Words: cardiovascular physiology • receptors, adrenergic, -2 • G-protein beta3 subunit • dexmedetomidine • pharmacogenetics • ethnic groups
This article has been cited by other articles:
 |
|
 |
|
  J. S. Floras Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J. Am. Coll. Cardiol., July 28, 2009; 54(5): 375 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rosskopf and M. C. Michel Pharmacogenomics of G Protein-Coupled Receptor Ligands in Cardiovascular Medicine Pharmacol. Rev., December 1, 2008; 60(4): 513 - 535. [Abstract] [Full Text] [PDF]
|
|